Common Shares, no par value
- Symbol
- BHVN
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02, 9.01 · 8-K
Biohaven Ltd.
BHVNNYSEEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 3, 2026, the Board of Directors (the “Board”) of Biohaven Ltd. (the “Company”) appointed John Yetimoglu as a director, effective August 6, 2026. Mr.…
Company context
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. The Company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.
Current securities
Registered securities in this filing
Biohaven Ltd. · 8-K · Filed 2026-08-07
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 3, 2026, the Board of Directors (the “Board”) of Biohaven Ltd. (the “Company”) appointed John Yetimoglu as a director, effective August 6, 2026. Mr. Yetimoglu will serve in the class of directors whose term will expire at the Company’s 2027 Annual Meeting of Shareholders. Mr. Yetimoglu has also been appointed as a member of the Nominating and Governance Committee of the Board.
There is no arrangement or understanding between Mr. Yetimoglu and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Yetimoglu and any of the Company’s other directors or executive officers. Since the beginning of the Company’s last fiscal year, there are no transactions in which the Company was or is to be a participant and in which Mr. Yetimoglu or any member of his immediate family had or will have any interest that are required to be reported under Item 404(a) of Regulation S-K.
In accordance with the Company’s compensation policy for non-employee directors, Mr. Yetimoglu is entitled to options to purchase the Company’s common shares with an aggregate grant date fair value of $713,875. The shares underlying these options will vest 25% on grant and 25% on each of the following three anniversaries of grant, subject to Mr. Yetimoglu’s continuous service through each vesting date. Additionally, Mr. Yetimoglu will be entitled to receive a $57,000 annual retainer for his service as a director and committee member.